Nucleic Acid Drugs

Driven by the accelerating global aging, the rising incidence of chronic diseases, and the increasing demand for precision medicine, the market for nucleic acid drugs is experiencing explosive growth. Nucleic acid drugs treat diseases by directly regulating the transcription and expression processes of genes. Commonly used ones in clinical practice include antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs) and messenger RNAs (mRNAs).

Characteristics of Nucleic Acid Drugs

Compared with traditional drug therapies such as small molecule drugs and protein drugs, nucleic acid drugs have advantages such as simple design, short research and development cycle, high success rate, strong specificity, and long-lasting effects. The application fields of nucleic acid drugs cover tumors, rare genetic diseases, cardiovascular diseases, and infectious diseases, among others.

Development of Nucleic Acid Drugs

• Sequence design

Sequence design is the source and core of nucleic acid drug development, including target selection and sequence optimization, which directly determine the effectiveness, safety and developability of the drug.

• Chemical modification and delivery system

Unmodified natural nucleic acid molecules have poor stability and weak targeting ability, and are difficult to cross biological barriers to reach targeted organs and cells. Chemical and delivery modification technologies are precisely the key enabling means to solve these bottlenecks. By chemically moderating the nucleic acid backbone, the ribose or base, the stability and targeting ability of nucleic acid drugs can be improved, delivery efficiency can be enhanced, and the immunogenicity of the drug can be reduced. The efficiency and safety of the delivery system determine the success or failure of the drugs.

Our Raw Materials for Nucleic Acid Drugs

From the nucleotide monomers required for the initial sequence synthesis, to the modified raw materials needed for stable molecules, and then to the lipids and target ligands required for the construction of delivery systems, the quality of each raw material directly affects the quality and efficacy of the final drug. As a globally leading supplier of nucleic acid drug raw materials, Protheragen is committed to providing the industry with comprehensive, reliable and innovative raw material solutions, jointly promoting the development of the nucleic acid drug field. Explore our raw material for nucleic acid drugs.

• Nucleotide

Nucleotides are the basic structural units of nucleic acid drugs. Our nucleotide products encompass NTPs, pseudouridines, modified nucleotides, and more, supporting diverse needs from basic research to commercial production.

• Lipid nanoparticles (LNP) Raw Materials

Lipid nanoparticles (LNP) are currently the most prominent nucleic acid delivery system. At Protheragen, we not only offer a wide range of high-quality LNP raw materials, but also provide lipid-based nanoparticle development services.

• GalNAc

GalNAc is a commonly used targeting ligand for siRNA drugs, which can specifically deliver the drugs to liver cells.

• Cap analogues

The 5'-end cap structure is a key modification for mRNA maturation and is crucial for enhancing translation efficiency and stability.

Nucleic acid drugs, with their unique mechanism of action and therapeutic advantages, are becoming the most disruptive and frontier directions in the field of biomedicine. Protheragen understands the significance of nucleic acid drug raw materials to the final drug, and is committed to building the most solid foundation for the successful research and commercial production of the new generation of nucleic acid drugs. If you are interested in our raw materials for nucleic acid drugs, please contact us.